JD Supra Law

FEBRUARY 13, 2024

Lundbeck A-S v. December 7, 2023), Plaintiffs, H. Lundbeck A/S (“Lundbeck”) and Takeda Pharmaceutical Company Ltd., collectively “Takeda”) appealed a District of Delaware ruling that several generic pharmaceutical company defendants’ Abbreviated New Drug Applications would not infringe its U.S.

Patent 103

Patent 103

Intellectual Property Law Blog

JANUARY 18, 2024

Lundbeck A/S, et al. 2021) to situations in which a generic pharmaceutical company engages in advertising or promotional activities for an infringing use. Plaintiffs (H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Lupin Ltd., The approved NDA is held by Takeda Pharmaceuticals U.S.A.,

Advertising 147

Advertising Advertising Marketing Marketing 147

Patently-O

DECEMBER 7, 2023

by Dennis Crouch H. Lundbeck A/S v. The Federal Circuit recently affirmed a district court judgment finding that Abbreviated New Drug Applications (“ANDAs”) submitted by generic drug manufacturers did not infringe patents rights held by H. Lupin Ltd. , 2022-1194, 2022-1208, 2022-1246 (Fed.

Patent 126

Patent Advertising Advertising Patent Infringement 126

JD Supra Law

JANUARY 19, 2024

Lundbeck A/S, et al. Lupin Ltd.,

Advertising 75

Advertising Advertising Patent 75

LexBlog IP

JANUARY 18, 2024

Lundbeck A/S, et al. This case affirms settled law that had become somewhat uncertain due to the Federal Circuit’s 2021 Glaxo opinion. 2021) to situations in which a generic pharmaceutical company engages in advertising or promotional activities for an infringing use. Plaintiffs (H. Lupin Ltd.,

Advertising 52

Advertising Advertising Marketing Marketing 52

IP Tech Blog

DECEMBER 20, 2023

In the case of H. Lundbeck A/S et al. The drug was originally developed by Lundbeck and later licensed to Takeda, who is the holder of the NDA. This strategy is contentious. It provides for competition but sometimes results in infringement due to off-label use of the generic drug – a delicate balance. Lupin et al. ,

Patent 62

Patent Litigation Marketing Marketing 62

LexBlog IP

DECEMBER 20, 2023

In the case of H. Lundbeck A/S et al. Takeda’s NDA for Trintellix ® (vortioxetine) Trintellix® (vortioxetine) is a drug for treating major depressive disorder in adults by enhancing serotonergic activity in the central nervous system. This strategy is contentious. Lupin et al. , FDA in 2013 under NDA No.

Patent 52

Patent Litigation Marketing Marketing 52